Oncolytics Biotech reported updated Phase 1 data for pelareorep combined with bevacizumab and FOLFIRI in second-line RAS-mutant microsatellite-stable colorectal cancer, highlighting a median duration of response of 19.5 months and a 33% overall response rate. The company said the results numerically exceed historical standard-of-care benchmarks and point to a durability signal it intends to leverage in regulatory discussions. Oncolytics also said investigators and the FDA are discussing a potential accelerated approval pathway for the intravenous oncolytic virus immunotherapy. The update is drawn from the REO 022 trial (NCT01274624) in patients with measurable metastatic disease and confirmed KRAS mutations. While still early-stage, the response-duration profile is central to how companies seek accelerated routes in oncology—especially when durable benefit can differentiate from prior chemotherapy-era expectations.